PL3919491T3 - Inhibitor akt - Google Patents

Inhibitor akt

Info

Publication number
PL3919491T3
PL3919491T3 PL20748221.7T PL20748221T PL3919491T3 PL 3919491 T3 PL3919491 T3 PL 3919491T3 PL 20748221 T PL20748221 T PL 20748221T PL 3919491 T3 PL3919491 T3 PL 3919491T3
Authority
PL
Poland
Prior art keywords
akt inhibitor
akt
inhibitor
Prior art date
Application number
PL20748221.7T
Other languages
English (en)
Polish (pl)
Inventor
Changyou MA
He Tian
Jie An
Jianliang Zhao
Donghui Chen
Jian Wu
Dan Xu
Chunxia ZHU
Zhoushan TIAN
Original Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. filed Critical Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
Publication of PL3919491T3 publication Critical patent/PL3919491T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL20748221.7T 2019-01-29 2020-01-22 Inhibitor akt PL3919491T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910084801 2019-01-29
PCT/CN2020/073798 WO2020156437A1 (zh) 2019-01-29 2020-01-22 Akt抑制剂

Publications (1)

Publication Number Publication Date
PL3919491T3 true PL3919491T3 (pl) 2025-10-20

Family

ID=71841634

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20748221.7T PL3919491T3 (pl) 2019-01-29 2020-01-22 Inhibitor akt

Country Status (10)

Country Link
US (1) US12617784B2 (cg-RX-API-DMAC7.html)
EP (1) EP3919491B1 (cg-RX-API-DMAC7.html)
JP (2) JP7617005B2 (cg-RX-API-DMAC7.html)
KR (1) KR102892239B1 (cg-RX-API-DMAC7.html)
CN (2) CN113272304B (cg-RX-API-DMAC7.html)
AU (1) AU2020214258B2 (cg-RX-API-DMAC7.html)
CA (1) CA3127884A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037595T3 (cg-RX-API-DMAC7.html)
PL (1) PL3919491T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020156437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂
US12673061B2 (en) 2020-07-22 2026-07-07 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Unit dosage composition of AKT inhibitor
EP4186902A4 (en) * 2020-07-22 2024-06-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF
JP7472391B2 (ja) * 2020-07-22 2024-04-22 南京正大天晴制薬有限公司 ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩及び結晶形
CN116478156A (zh) * 2022-01-17 2023-07-25 南京正大天晴制药有限公司 一种akt抑制剂化合物的富马酸盐晶型及其制备方法
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
CN121586576A (zh) 2023-06-14 2026-02-27 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
CN120157686A (zh) * 2023-12-14 2025-06-17 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用
CN121177294B (zh) * 2025-11-27 2026-02-27 四川省医学科学院·四川省人民医院 Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004293026B2 (en) * 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
RU2481336C2 (ru) * 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US20130065908A1 (en) * 2009-12-07 2013-03-14 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
CN104876921A (zh) * 2008-01-09 2015-09-02 阵列生物制药公司 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
AR093512A1 (es) * 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
AR093511A1 (es) * 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CN108503645A (zh) * 2018-03-01 2018-09-07 山东大学 含氨甲基的哌嗪酮类化合物及其制备方法和应用
EP3784669B1 (en) * 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof

Also Published As

Publication number Publication date
KR102892239B1 (ko) 2025-11-26
JP2022517866A (ja) 2022-03-10
CN117964620A (zh) 2024-05-03
KR20210120054A (ko) 2021-10-06
EP3919491A4 (en) 2022-10-19
AU2020214258B2 (en) 2025-08-28
US12617784B2 (en) 2026-05-05
EP3919491B1 (en) 2025-05-28
US20220144821A1 (en) 2022-05-12
EP3919491C0 (en) 2025-05-28
CA3127884A1 (en) 2020-08-06
CN113272304B (zh) 2024-03-29
AU2020214258A1 (en) 2021-09-16
ES3037595T3 (en) 2025-10-03
WO2020156437A1 (zh) 2020-08-06
JP7617005B2 (ja) 2025-01-17
EP3919491A1 (en) 2021-12-08
CN113272304A (zh) 2021-08-17
JP2024175091A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
IL287767A (en) cdk inhibitors
ZA202106284B (en) Rad51 inhibitors
GB201914860D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
CA188849S (en) Showerhead
GB201905328D0 (en) Inhibitor compounds
EP3889861C0 (en) 3D URL
CA195194S (en) Can
EP4025564A4 (en) NITRIFICATION INHIBITORS
CA188846S (en) Showerhead
EP4263533C0 (en) Erap inhibitors
CA188847S (en) Showerhead
EP4019048A4 (en) ABCC11 INHIBITOR
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
HK40071165A (en) Inhibiting usp19
HK40070698A (en) Inhibiting usp36
CA195860S (en) Showerhead
EP4049722A4 (en) PROLIFERATION INHIBITOR
GB201905318D0 (en) Inhibitor compounds
CA190993S (en) Showerhead
CA190568S (en) Showerhead
CA190450S (en) Showerhead
CA190446S (en) Showerhead
CA190449S (en) Showerhead